On August 3, 2022 Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, reported that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Canaccord Genuity 42ND Annual Growth Conference on Wednesday, August 10, 2022 at 1 p.m. Eastern (Press release, Neoleukin Therapeutics, AUG 3, 2022, View Source [SID1234617405]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast presentation can be accessed from the investors section of the Neoleukin website at View Source An archived replay will also be available on the company website for at least 30 days following the event.